메뉴 건너뛰기




Volumn 9, Issue 5, 2007, Pages 391-398

Mantle cell lymphoma: Evolving novel options

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BBR 2778; BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CARFILZOMIB; CMC 544; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; IBRITUMOMAB TIUXETAN; IPILIMUMAB; IXABEPILONE; LENALIDOMIDE; MITOXANTRONE; PIXANTRONE; PR 171; PREDNISONE; RITUXIMAB; SDX 105; THALIDOMIDE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE; Y 2121;

EID: 34548537217     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-007-0053-9     Document Type: Review
Times cited : (17)

References (67)
  • 1
    • 28844449677 scopus 로고    scopus 로고
    • Cyclin D1-negative mantle cell lymphoma: A clinicopathologic study based on gene expression profiling
    • Fu K, Weisenburger DD, Greiner TC, et al.: Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005, 106:4315-4321.
    • (2005) Blood , vol.106 , pp. 4315-4321
    • Fu, K.1    Weisenburger, D.D.2    Greiner, T.C.3
  • 2
    • 27244434794 scopus 로고    scopus 로고
    • Pathogenesis of mande-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways
    • Fernandez V, Hartmann E, Ott G, et al.: Pathogenesis of mande-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005, 23:6364-6369.
    • (2005) J Clin Oncol , vol.23 , pp. 6364-6369
    • Fernandez, V.1    Hartmann, E.2    Ott, G.3
  • 3
    • 3242762286 scopus 로고    scopus 로고
    • Genomic DNA-chip hybridization in t(11, 14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions
    • Kohlhammer H, Schwaenen C, Wessendorf S, et al.: Genomic DNA-chip hybridization in t(11, 14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004, 104:795-801.
    • (2004) Blood , vol.104 , pp. 795-801
    • Kohlhammer, H.1    Schwaenen, C.2    Wessendorf, S.3
  • 4
    • 0013224058 scopus 로고    scopus 로고
    • The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
    • Rosenwald A, Wright G, Wiestner A, et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
    • (2003) Cancer Cell , vol.3 , pp. 185-197
    • Rosenwald, A.1    Wright, G.2    Wiestner, A.3
  • 5
    • 33645729415 scopus 로고    scopus 로고
    • The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma
    • Katzenberger T, Petzoldt C, Holler S, et al.: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006, 107:3407.
    • (2006) Blood , vol.107 , pp. 3407
    • Katzenberger, T.1    Petzoldt, C.2    Holler, S.3
  • 6
    • 0035158697 scopus 로고    scopus 로고
    • Leukemic mantle cell lymphoma: Clinical and pathologic spectrum of twenty-three cases
    • Schlette E, Lai R, Onciu M, et al.: Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. Mod Pathol 2001, 14:1133-1140.
    • (2001) Mod Pathol , vol.14 , pp. 1133-1140
    • Schlette, E.1    Lai, R.2    Onciu, M.3
  • 7
    • 33644786965 scopus 로고    scopus 로고
    • Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
    • Pott C, Schrader C, Gesk S, et al.: Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271-2278.
    • (2006) Blood , vol.107 , pp. 2271-2278
    • Pott, C.1    Schrader, C.2    Gesk, S.3
  • 8
    • 0141889260 scopus 로고    scopus 로고
    • VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: Correlation with genomic aberrations, clinical characteristics, and outcome
    • Kienle D, Krober A, Katzenberger T, et al.: VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003, 102:3003-3009.
    • (2003) Blood , vol.102 , pp. 3003-3009
    • Kienle, D.1    Krober, A.2    Katzenberger, T.3
  • 9
    • 34548523417 scopus 로고    scopus 로고
    • A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma
    • Hoster E, Dreyling N, Unterhalt M, et al.: A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2006, 108:814.
    • (2006) Blood , vol.108 , pp. 814
    • Hoster, E.1    Dreyling, N.2    Unterhalt, M.3
  • 10
    • 0031788754 scopus 로고    scopus 로고
    • Management of mantle cell lymphoma
    • Armitage JO: Management of mantle cell lymphoma. Oncology (Williston Park) 1998, 12:49-55.
    • (1998) Oncology (Williston Park) , vol.12 , pp. 49-55
    • Armitage, J.O.1
  • 11
    • 0037301982 scopus 로고    scopus 로고
    • Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
    • Romaguera JE, Medeiros LJ, Hagemeister FB, et al.: Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003, 97:586-591.
    • (2003) Cancer , vol.97 , pp. 586-591
    • Romaguera, J.E.1    Medeiros, L.J.2    Hagemeister, F.B.3
  • 12
    • 0036499084 scopus 로고    scopus 로고
    • Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
    • Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288-1294.
    • (2002) J Clin Oncol , vol.20 , pp. 1288-1294
    • Howard, O.M.1    Gribben, J.G.2    Neuberg, D.S.3
  • 13
    • 0032422078 scopus 로고    scopus 로고
    • Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
    • Khouri IF, Romaguera J, Kantarjian H, et al.: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.
    • (1998) J Clin Oncol , vol.16 , pp. 3803-3809
    • Khouri, I.F.1    Romaguera, J.2    Kantarjian, H.3
  • 14
    • 27244452464 scopus 로고    scopus 로고
    • High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    • Romaguera JE, Fayad L, Rodriguez MA, et al.: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013-7023.
    • (2005) J Clin Oncol , vol.23 , pp. 7013-7023
    • Romaguera, J.E.1    Fayad, L.2    Rodriguez, M.A.3
  • 15
    • 33645590231 scopus 로고    scopus 로고
    • Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: A Wisconsin Oncology Network Study [abstract]
    • Kahl BS, McGovern, Blank J, et al.: Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: A Wisconsin Oncology Network Study [abstract]. Blood 2004, 104:1388.
    • (2004) Blood , vol.104 , pp. 1388
    • Kahl, B.S.1
  • 16
    • 0031896096 scopus 로고    scopus 로고
    • Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas
    • Decaudin D, Bosq J, Tertian G, et al.: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998, 16:579-583.
    • (1998) J Clin Oncol , vol.16 , pp. 579-583
    • Decaudin, D.1    Bosq, J.2    Tertian, G.3
  • 17
    • 0034845543 scopus 로고    scopus 로고
    • Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
    • Cohen BJ, Moskowitz C, Straus D, et al.: Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001, 42:1015-1022.
    • (2001) Leuk Lymphoma , vol.42 , pp. 1015-1022
    • Cohen, B.J.1    Moskowitz, C.2    Straus, D.3
  • 18
    • 8744274334 scopus 로고    scopus 로고
    • The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    • Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
    • (2004) Blood , vol.104 , pp. 3064-3071
    • Forstpointner, R.1    Dreyling, M.2    Repp, R.3
  • 19
    • 33845693025 scopus 로고    scopus 로고
    • The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma
    • Ritchie DS, Seymour JF, Grigg AP, et al.: The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007, 86:101-105.
    • (2007) Ann Hematol , vol.86 , pp. 101-105
    • Ritchie, D.S.1    Seymour, J.F.2    Grigg, A.P.3
  • 20
    • 85014234123 scopus 로고    scopus 로고
    • Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: A prospective study
    • Lefrere F, Delmer A, Suzan F, et al.: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587-593.
    • (2002) Leukemia , vol.16 , pp. 587-593
    • Lefrere, F.1    Delmer, A.2    Suzan, F.3
  • 21
    • 0642368565 scopus 로고    scopus 로고
    • Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma
    • Khouri IF, Lee MS, Saliba RM, et al.: Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407-4412.
    • (2003) J Clin Oncol , vol.21 , pp. 4407-4412
    • Khouri, I.F.1    Lee, M.S.2    Saliba, R.M.3
  • 22
    • 20644469242 scopus 로고    scopus 로고
    • Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
    • Rummel MJ, Al-Batran SE, Kim SZ, et al.: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
    • (2005) J Clin Oncol , vol.23 , pp. 3383-3389
    • Rummel, M.J.1    Al-Batran, S.E.2    Kim, S.Z.3
  • 23
    • 33748319711 scopus 로고    scopus 로고
    • Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract]
    • Zelenetz A, Noy A, Pandit-Taskar M, et al.: Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract]. J Clin Oncol Proc ASCO 2006, 24:7560
    • (2006) J Clin Oncol Proc ASCO , vol.24 , pp. 7560
    • Zelenetz, A.1    Noy, A.2    Pandit-Taskar, M.3
  • 24
    • 33748324856 scopus 로고    scopus 로고
    • Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patents with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499) [abstract]
    • Smith M, Chen H, Gordon L, Horning S: Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patents with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499) [abstract]. J Clin Oncol 2006, 24:7503.
    • (2006) J Clin Oncol , vol.24 , pp. 7503
    • Smith, M.1    Chen, H.2    Gordon, L.3    Horning, S.4
  • 25
    • 24344492734 scopus 로고    scopus 로고
    • A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]
    • Oki Y, Pro B, Depassand E, et al.: A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]. Blood 2004, 104:2632.
    • (2004) Blood , vol.104 , pp. 2632
    • Oki, Y.1    Pro, B.2    Depassand, E.3
  • 26
    • 0036566227 scopus 로고    scopus 로고
    • High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
    • Gopal AK, Rajendran JG, Petersdorf SH, et al.: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158-3162.
    • (2002) Blood , vol.99 , pp. 3158-3162
    • Gopal, A.K.1    Rajendran, J.G.2    Petersdorf, S.H.3
  • 27
    • 34548525578 scopus 로고    scopus 로고
    • Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results [abstract]
    • Morschhauser F, Leonard JP, Fayad L, et al.: Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results [abstract]. J Clin Oncol 2007, 25:8032.
    • (2007) J Clin Oncol , vol.25 , pp. 8032
    • Morschhauser, F.1    Leonard, J.P.2    Fayad, L.3
  • 28
    • 34548540008 scopus 로고    scopus 로고
    • Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL) [abstract]
    • Advani A, Giné E, Gisselbrecht C, et al.: Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Blood 2005, 106:230.
    • (2005) Blood , vol.106 , pp. 230
    • Advani, A.1    Giné, E.2    Gisselbrecht, C.3
  • 29
    • 33748110441 scopus 로고    scopus 로고
    • A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma [abstract]
    • Advani R, Furman R, Rosenblatt J, et al.: A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma [abstract]. Blood 2005, 108:1504.
    • (2005) Blood , vol.108 , pp. 1504
    • Advani, R.1    Furman, R.2    Rosenblatt, J.3
  • 30
    • 33646390886 scopus 로고    scopus 로고
    • Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) [abstract]
    • Younes Y, Vose J, Zelenetz A, et al.: Results of a phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL) [abstract]. Blood 2005, 106:489.
    • (2005) Blood , vol.106 , pp. 489
    • Younes, Y.1    Vose, J.2    Zelenetz, A.3
  • 31
    • 24744457075 scopus 로고    scopus 로고
    • Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
    • Neelapu SS, Kwak LW, Kobrin CB, et al.: Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005, 11:986-991.
    • (2005) Nat Med , vol.11 , pp. 986-991
    • Neelapu, S.S.1    Kwak, L.W.2    Kobrin, C.B.3
  • 32
    • 33644659256 scopus 로고    scopus 로고
    • Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
    • Peggs KS, Quezada SA, Korman AJ, Allison JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006, 18:206-213.
    • (2006) Curr Opin Immunol , vol.18 , pp. 206-213
    • Peggs, K.S.1    Quezada, S.A.2    Korman, A.J.3    Allison, J.P.4
  • 33
    • 2342613652 scopus 로고    scopus 로고
    • The proteasome: A suitable antineoplastic target
    • Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360.
    • (2004) Nat Rev Cancer , vol.4 , pp. 349-360
    • Adams, J.1
  • 34
    • 34548526934 scopus 로고    scopus 로고
    • Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas [abstract]
    • Goy A, East K, Mesina F, et al.: Report of a phase II study of proteasome inhibitor bortezomib in patients with relapsed or refractory indolent and aggressive B-cell lymphomas [abstract]. J Clin Oncol Proc ASCO 2003, 22:2291.
    • (2003) J Clin Oncol Proc ASCO , vol.22 , pp. 2291
    • Goy, A.1    East, K.2    Mesina, F.3
  • 35
    • 20044376092 scopus 로고    scopus 로고
    • Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    • O'Connor OA, Wright J, Moskowitz C, et al.: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
    • (2005) J Clin Oncol , vol.23 , pp. 676-684
    • O'Connor, O.A.1    Wright, J.2    Moskowitz, C.3
  • 36
    • 23644452770 scopus 로고    scopus 로고
    • Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) [abstract]
    • Strauss S, Maharaj L, Jim Stec J, et al.: Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) [abstract]. Blood 2004, 104:1386.
    • (2004) Blood , vol.104 , pp. 1386
    • Strauss, S.1    Maharaj, L.2    Jim Stec, J.3
  • 37
    • 16844367553 scopus 로고    scopus 로고
    • Phase II trial of bortezomib in mantle cell lymphoma [abstract]. Oral Session
    • Belch A, Kouroukis C, Crump M, et al.: Phase II trial of bortezomib in mantle cell lymphoma [abstract]. Oral Session. Blood 2004, 104:608.
    • (2004) Blood , vol.104 , pp. 608
    • Belch, A.1    Kouroukis, C.2    Crump, M.3
  • 38
    • 34548522609 scopus 로고    scopus 로고
    • Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study [abstract]
    • Goy A, Bernstein S, Kahl BS, et al.: Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): results of the PINNACLE study [abstract]. J Clin Oncol Proc ASCO 2006, 24:7512.
    • (2006) J Clin Oncol Proc ASCO , vol.24 , pp. 7512
    • Goy, A.1    Bernstein, S.2    Kahl, B.S.3
  • 39
    • 33750625445 scopus 로고    scopus 로고
    • Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    • Fisher RI, Bernstein S, Kahl BS, et al.: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
    • (2006) J Clin Oncol , vol.24 , pp. 4867-4874
    • Fisher, R.I.1    Bernstein, S.2    Kahl, B.S.3
  • 40
    • 33746428098 scopus 로고    scopus 로고
    • Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells [abstract]
    • Goy A, Remache Y, Barkoh, et al.: Sensitivity, schedule-dependence and molecular effects of the proteasome inhibitor bortezomib in non-Hodgkin's lymphoma cells [abstract]. Blood 2004, 104:389a.
    • (2004) Blood , vol.104
    • Goy, A.1    Remache, Y.2    Barkoh3
  • 41
    • 20044396543 scopus 로고    scopus 로고
    • Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma
    • Goy A, Younes A, McLaughlin P, et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
    • (2005) J Clin Oncol , vol.23 , pp. 667-675
    • Goy, A.1    Younes, A.2    McLaughlin, P.3
  • 42
    • 33746010219 scopus 로고    scopus 로고
    • Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
    • Richardson PG, Briemberg H, Jagannath S, et al.: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
    • (2006) J Clin Oncol , vol.24 , pp. 3113-3120
    • Richardson, P.G.1    Briemberg, H.2    Jagannath, S.3
  • 43
    • 33746056833 scopus 로고    scopus 로고
    • Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?
    • Gerecitano J, Goy A, Wright J, et al.: Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006, 134:391-398.
    • (2006) Br J Haematol , vol.134 , pp. 391-398
    • Gerecitano, J.1    Goy, A.2    Wright, J.3
  • 44
    • 34250900229 scopus 로고    scopus 로고
    • Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: Final results. Oral Session
    • De Vos S, Dakhil SR, McLaughlin P, et al.: Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with follicular (FL) or marginal zone (MZL) lymphoma: final results. Oral Session. Blood 2006; 108.
    • (2006) Blood , pp. 108
    • De Vos, S.1    Dakhil, S.R.2    McLaughlin, P.3
  • 45
    • 34548541174 scopus 로고    scopus 로고
    • Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)
    • O'Connor O, Hamlin P, Moskowitz C, et al.: Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL). J Clin Oncol 2007, 25:8051.
    • (2007) J Clin Oncol , vol.25 , pp. 8051
    • O'Connor, O.1    Hamlin, P.2    Moskowitz, C.3
  • 46
    • 33847297956 scopus 로고    scopus 로고
    • Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma
    • Weigert O, Pastore A, Rieken M, et al.: Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007, 21:524-528.
    • (2007) Leukemia , vol.21 , pp. 524-528
    • Weigert, O.1    Pastore, A.2    Rieken, M.3
  • 47
    • 34247517943 scopus 로고    scopus 로고
    • Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma
    • Drach J, Kaufmann H, Pichelmayer O, et al.: Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma. J Clin Oncol 2006, 24:17522.
    • (2006) J Clin Oncol , vol.24 , pp. 17522
    • Drach, J.1    Kaufmann, H.2    Pichelmayer, O.3
  • 48
    • 33745892167 scopus 로고    scopus 로고
    • Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results [abstract]
    • Leonard J, Furman R, Feldman E, et al.: Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results [abstract]. Blood 2005, 104:491.
    • (2005) Blood , vol.104 , pp. 491
    • Leonard, J.1    Furman, R.2    Feldman, E.3
  • 49
    • 35348876311 scopus 로고    scopus 로고
    • Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [abstract]
    • Mounier N, Ribrag V, Haioun C, et al.: Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: A randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) [abstract]. J Clin Oncol 2007, 25:8010.
    • (2007) J Clin Oncol , vol.25 , pp. 8010
    • Mounier, N.1    Ribrag, V.2    Haioun, C.3
  • 50
    • 34548537359 scopus 로고    scopus 로고
    • Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses
    • Stewart KA, O'Connor OA, Alsina M, et al.: Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses. J Clin Oncol 2007, 25:8003.
    • (2007) J Clin Oncol , vol.25 , pp. 8003
    • Stewart, K.A.1    O'Connor, O.A.2    Alsina, M.3
  • 51
    • 23944481410 scopus 로고    scopus 로고
    • Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    • Witzig TE, Geyer SM, Ghobrial I, et al.: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347-5356.
    • (2005) J Clin Oncol , vol.23 , pp. 5347-5356
    • Witzig, T.E.1    Geyer, S.M.2    Ghobrial, I.3
  • 52
    • 33747846726 scopus 로고    scopus 로고
    • Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
    • Rudelius M, Pittaluga S, Nishizuka S, et al.: Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.
    • (2006) Blood , vol.108 , pp. 1668-1676
    • Rudelius, M.1    Pittaluga, S.2    Nishizuka, S.3
  • 53
    • 33749002279 scopus 로고    scopus 로고
    • Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
    • Yee KW, Zeng Z, Konopleva M, et al.: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006, 12:5165-5173.
    • (2006) Clin Cancer Res , vol.12 , pp. 5165-5173
    • Yee, K.W.1    Zeng, Z.2    Konopleva, M.3
  • 54
    • 33645635326 scopus 로고    scopus 로고
    • A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies
    • Feldman E, Giles F, Roboz G, et al.: A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 2005, 23:6631.
    • (2005) J Clin Oncol , vol.23 , pp. 6631
    • Feldman, E.1    Giles, F.2    Roboz, G.3
  • 55
    • 4944229959 scopus 로고    scopus 로고
    • Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma
    • Kaufmann H, Raderer M, Wohrer S, et al.: Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004, 104:2269-2271.
    • (2004) Blood , vol.104 , pp. 2269-2271
    • Kaufmann, H.1    Raderer, M.2    Wohrer, S.3
  • 56
    • 34147181695 scopus 로고    scopus 로고
    • Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma
    • Witzig TE, Vose JM, Kaplan HP, et al.: Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood 2006, 108:2482.
    • (2006) Blood , vol.108 , pp. 2482
    • Witzig, T.E.1    Vose, J.M.2    Kaplan, H.P.3
  • 57
    • 34548539145 scopus 로고    scopus 로고
    • A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/ refractory mantle cell lymphoma (MCL) with early evidence of efficacy
    • Wang M, Fayad L, Hagemeister F, et al.: A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/ refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 2007, 25:8030.
    • (2007) J Clin Oncol , vol.25 , pp. 8030
    • Wang, M.1    Fayad, L.2    Hagemeister, F.3
  • 58
    • 34548542892 scopus 로고    scopus 로고
    • A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma
    • Younes A, Fanale M, Pro B, et al.: A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Ontology 2007, 25:8000.
    • (2007) J Clin Ontology , vol.25 , pp. 8000
    • Younes, A.1    Fanale, M.2    Pro, B.3
  • 59
    • 33644836549 scopus 로고    scopus 로고
    • Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    • O'Connor OA, Heaney ML, Schwartz L, et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166-173.
    • (2006) J Clin Oncol , vol.24 , pp. 166-173
    • O'Connor, O.A.1    Heaney, M.L.2    Schwartz, L.3
  • 60
    • 33644873930 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma
    • Heider U, Kaiser M, Sterz J, et al.: Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006, 76:42-50.
    • (2006) Eur J Haematol , vol.76 , pp. 42-50
    • Heider, U.1    Kaiser, M.2    Sterz, J.3
  • 61
    • 34248362003 scopus 로고    scopus 로고
    • The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak
    • Perez-Galan P, Roue G, Villamor N, et al.: The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109:4441-4449.
    • (2007) Blood , vol.109 , pp. 4441-4449
    • Perez-Galan, P.1    Roue, G.2    Villamor, N.3
  • 62
    • 0038473927 scopus 로고    scopus 로고
    • Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group
    • Kouroukis CT, Belch A, Crump M, et al.: Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1740-1745.
    • (2003) J Clin Oncol , vol.21 , pp. 1740-1745
    • Kouroukis, C.T.1    Belch, A.2    Crump, M.3
  • 63
    • 33846219417 scopus 로고    scopus 로고
    • Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
    • Byrd JC, Lin TS, Dalton JT, et al.: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109:399-404.
    • (2007) Blood , vol.109 , pp. 399-404
    • Byrd, J.C.1    Lin, T.S.2    Dalton, J.T.3
  • 64
    • 33747890672 scopus 로고    scopus 로고
    • Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma
    • Lin TS, Fischer B, Moran M, et al.: Flavopiridol, fludarabine and rituximab is a highly active regimen in indolent B-cell lymphoproliferative disorders including mantle cell lymphoma. Blood 2005, 106:944.
    • (2005) Blood , vol.106 , pp. 944
    • Lin, T.S.1    Fischer, B.2    Moran, M.3
  • 65
    • 34249075706 scopus 로고    scopus 로고
    • Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
    • Robertson MJ, Kahl BS, Vose JM, et al.: Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:1741-1746.
    • (2007) J Clin Oncol , vol.25 , pp. 1741-1746
    • Robertson, M.J.1    Kahl, B.S.2    Vose, J.M.3
  • 66
    • 0038206722 scopus 로고    scopus 로고
    • Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis
    • Pham LV, Tamayo AT, Yoshimura LC, et al.: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003, 171:88-95.
    • (2003) J Immunol , vol.171 , pp. 88-95
    • Pham, L.V.1    Tamayo, A.T.2    Yoshimura, L.C.3
  • 67
    • 0141953292 scopus 로고    scopus 로고
    • Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resisance in lymphoma cells
    • Chauhan D, Li G, Shringarpure R, et al.: Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resisance in lymphoma cells. Cancer Res 2003, 63:6174-6177.
    • (2003) Cancer Res , vol.63 , pp. 6174-6177
    • Chauhan, D.1    Li, G.2    Shringarpure, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.